Compare AOSL & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AOSL | MDXG |
|---|---|---|
| Founded | 2000 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 940.9M | 1.0B |
| IPO Year | 2010 | N/A |
| Metric | AOSL | MDXG |
|---|---|---|
| Price | $22.57 | $5.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $24.33 | $11.00 |
| AVG Volume (30 Days) | 298.0K | ★ 931.7K |
| Earning Date | 02-05-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | ★ $696,776,000.00 | $393,442,000.00 |
| Revenue This Year | N/A | $19.13 |
| Revenue Next Year | $6.59 | $2.11 |
| P/E Ratio | ★ N/A | $20.07 |
| Revenue Growth | 5.81 | ★ 14.77 |
| 52 Week Low | $15.90 | $5.39 |
| 52 Week High | $46.65 | $9.36 |
| Indicator | AOSL | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 61.53 | 21.91 |
| Support Level | $21.86 | $5.55 |
| Resistance Level | $22.56 | $6.50 |
| Average True Range (ATR) | 0.70 | 0.22 |
| MACD | 0.22 | -0.11 |
| Stochastic Oscillator | 77.84 | 2.55 |
Alpha & Omega Semiconductor Ltd designs, develops and supplies a portfolio of power semiconductors targeting various applications, including personal computers, flat-panel TVs, LED lighting, smartphones, battery packs, consumer and industrial motor controls and power supplies for TVs, computers, servers and telecommunications equipment. It generates revenue mainly from the sale of power semiconductors, consisting of power discretes and power ICs with a presence in Hong Kong, China, South Korea, the United States and other countries. It operates in one operating segment: the design, development and supply of power semiconductor products for computing, consumer electronics, communication and industrial applications.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.